Show simple item record

dc.contributor.authorForootan, FSen
dc.contributor.authorForootan, SSen
dc.contributor.authorGou, Xen
dc.contributor.authorYang, Jen
dc.contributor.authorLiu, Ben
dc.contributor.authorChen, Den
dc.contributor.authorAl Fayi, MSen
dc.contributor.authorAl-Jameel, Wen
dc.contributor.authorRudland, PSen
dc.contributor.authorHussain, SAen
dc.contributor.authorKe, Yen
dc.date.accessioned2018-01-22T11:17:58Z
dc.date.available2018-01-22T11:17:58Z
dc.date.issued2016-02-23en
dc.identifier.urihttp://hdl.handle.net/10026.1/10633
dc.description.abstract

In previous work, it is suggested that the excessive amount of fatty acids transported by FABP5 may facilitate the malignant progression of prostate cancer cells through a FABP5-PPARγ-VEGF signal transduction axis to increase angiogenesis. To further functionally characterise the FABP5-PPARγ-VEGF signal transduction pathway, we have, in this work, investigated the molecular mechanisms involved in its tumorigenicity promoting role in prostate cancer. Suppression of PPARγ in highly malignant prostate cancer cells produced a significant reduction (up to 53%) in their proliferation rate, invasiveness (up to 89%) and anchorage-independent growth (up to 94%) in vitro. Knockdown of PPARγ gene in PC3-M cells by siRNA significantly reduced the average size of tumours formed in nude mice by 99% and tumour incidence by 90%, and significantly prolonged the latent period by 3.5 fold. Results in this study combined with some previous results suggested that FABP5 promoted VEGF expression and angiogenesis through PPARγ which was activated by fatty acids transported by FABP5. Further investigations showed that PPARγ up-regulated VEGF expression through acting with the PPAR-responsive elements in the promoter region of VEGF gene in prostate cancer cells. Although androgen can modulate VEGF expression through Sp1/Sp3 binding site on VEGF promoter in androgen-dependent prostate cancer cells, this route, disappeared as the cells gradually lost their androgen dependency; was replaced by the FABP5-PPARγ-VEGF signalling pathway. These results suggested that the FABP5-PPARγ-VEGF signal transduction axis, rather than androgen modulated route, may be a more important novel therapeutic target for angiogenesis-suppression treatment of castration resistant prostate cancer.

en
dc.format.extent9322 - 9339en
dc.languageengen
dc.language.isoengen
dc.subjectFABP5en
dc.subjectPPARγen
dc.subjectPPREen
dc.subjectVEGFen
dc.subjectprostate canceren
dc.subjectAnimalsen
dc.subjectBinding Sitesen
dc.subjectCell Line, Tumoren
dc.subjectCell Proliferationen
dc.subjectCell Transformation, Neoplasticen
dc.subjectFatty Acid-Binding Proteinsen
dc.subjectFatty Acidsen
dc.subjectGene Expression Regulation, Neoplasticen
dc.subjectHuman Umbilical Vein Endothelial Cellsen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiceen
dc.subjectMice, Inbred BALB Cen
dc.subjectMice, Nudeen
dc.subjectNeoplasm Invasivenessen
dc.subjectNeovascularization, Pathologicen
dc.subjectPPAR gammaen
dc.subjectPromoter Regions, Geneticen
dc.subjectProstateen
dc.subjectProstatic Neoplasms, Castration-Resistanten
dc.subjectRNA Interferenceen
dc.subjectRNA, Small Interferingen
dc.subjectSignal Transductionen
dc.subjectVascular Endothelial Growth Factor Aen
dc.titleFatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.en
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/26814431en
plymouth.issue8en
plymouth.volume7en
plymouth.publication-statusPublisheden
plymouth.journalOncotargeten
dc.identifier.doi10.18632/oncotarget.6975en
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
dc.publisher.placeUnited Statesen
dcterms.dateAccepted2016-01-17en
dc.identifier.eissn1949-2553en
dc.rights.embargoperiodNot knownen
rioxxterms.versionofrecord10.18632/oncotarget.6975en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2016-02-23en
rioxxterms.typeJournal Article/Reviewen


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV